1. Why New Treatments for Schizophrenia Should Be on Your Radar

2. Background

3. Program Objectives

4. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

5. Monitoring Drug Levels in Patients With Schizophrenia

6. The Importance of Monitoring Drug Levels

7. Poor Treatment Response in Schizophrenia

8. Rates of Subtherapeutic Drug Levels Are High

9. Effects of Drug Metabolism

10. Clinical Considerations for Plasma Drug Level Testing

11. Urine Drug Level Testing

12. Take-Home Messages

13. Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia

14. Topics for Discussion

15. A Brief Review of Biostatistics

16. NNT With Aripiprazole Lauroxil vs Placebo for PANSS Reduction

17. NNH and AE Rates With Aripiprazole Lauroxil vs Placebo

18. Clinical Considerations for Use of LAI Antipsychotics

19. Questions to Guide LAI Selection

20. Distinguishing Features of Available LAI Antipsychotics

21. Scientific Advances in the Biology of Schizophrenia: Focus on Mitochondrial Dysfunction

22. Topics for Discussion

23. Clinical Effects of Immune Dysregulation in Schizophrenia

24. A Brief Review of Mitochondria Action

25. Broad Effects of Mitochondrial Dysfunction

26. Looking Ahead: Targeting Mitochondria Therapeutically

27. Conclusions

28. New and Emerging Treatments for Schizophrenia: Part I

29. Relapse and Plasma Drug Levels After Discontinuation of Cariprazine

30. Relapse and Plasma Drug Levels After Discontinuation of Cariprazine: Results

31. Effect of Drug Half-Life on Relapse After Discontinuing Cariprazine

32. Effect of BI 409306 on PANSS: Phase 2 Trial

33. Effect of BI 409306 on PANSS: Results

34. Take-Home Messages

35. New and Emerging Treatments for Schizophrenia: Part II

36. Lumateperone: MOA

37. Lumateperone: Summary of Three Phase 3 Trials

38. Lumateperone Open-Label Switching Study: Design

39. Lumateperone Open-Label Switching Study: Safety

40. Lumateperone: Somnolence

41. Lumateperone Open-Label Switching Study: Efficacy

42. Take-Home Messages

43. Abbreviations

44. Abbreviations (cont)